DGAP-News

STADA Arzneimittel AG: Figures for the first half of 2015 benefit from substantially improved development in Q2/2015 - Central Europe as well as Asia/Pacific & MENA with excellent development, CIS/Eastern Europe stabilized considerably

DGAP-News: STADA Arzneimittel AG / Key word(s): Half Year Results
STADA Arzneimittel AG: Figures for the first half of 2015 benefit from
substantially improved development in Q2/2015 - Central Europe as well
as Asia/Pacific & MENA with excellent development, CIS/Eastern Europe
stabilized considerably

06.08.2015 / 07:25

---------------------------------------------------------------------

Important items at a glance
- Group sales rise by 2 percent - adjusted +2 percent

- Sales increases in Central Europe (+7 percent) as well as Asia/Pacific
& MENA (+67 percent) - sales in Russia in local currency approximately
at the level of the previous year

- Adjusted EBITDA decreases by 9 percent

- Adjusted net income declines by 6 percent

- Outlook for 2015 confirmed


STADA key figures

                             1-6/2015             1-6/2014             +/-

Group sales                  Euro 1,025.9 million Euro 1,002.8 million +2%

EBITDA, reported             Euro 181.4 million   Euro 192.1 million   -6%

EBITDA, adjusted             Euro 189.2 million   Euro 208.3 million   -9%

Net income, reported         Euro 53.6 million    Euro 66.8 million    -20%

Net income, adjusted         Euro 85.0 million    Euro 90.1 million    -6%

Earnings per share, reported Euro 0.88            Euro 1.11            -21%

Earnings per share, adjusted Euro 1.39            Euro 1.49            -7%

Bad Vilbel, August 6, 2015 - In the first half of 2015, the STADA Group
continued to be confronted with tremendous challenges particularly in the
market region CIS/ Eastern Europe. Due to a considerable stabilization of
the sales trend in Russia and excellent development in the market regions
Central Europe as well as Asia/Pacific & MENA, however, both reported and
adjusted Group sales were increased. Overall, the Group had to report
one-time special effects in connection with currency translation expenses
recorded in the income statement as a result of the weak Russian ruble and
the strong devaluation of the Ukrainian hryvnia in the total amount of
Euro 8.6 million before or Euro 7.0 million after taxes.

"The framework conditions in the market region CIS/Eastern Europe continue
to present a tremendous challenge. It is all the more pleasing that sales
in Russia in the first half of 2015 in local currency were approximately at
the same level of the corresponding period of the previous year and that
the sales trend there stabilized considerably compared to the first quarter
of 2015", said Hartmut Retzlaff, Chairman of the Executive Board of STADA
Arzneimittel AG.

Development of sales
Group sales in the first 6 months of 2015 increased by 2 percent to Euro